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Background: To investigate the risk of hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients with
HBV carrier state during treatment of disease-modifying antirheumatic drugs (DMARDs) and the use of antiviral
prophylaxis in real-world clinical practice.
Methods: Consecutive RA patients with HBV carrier state were included. Clinical data including liver evaluation, HBV
infection evaluation and the use of antiviral prophylaxis were recorded.
Results: Fifty-three RA patients with HBV carrier state were screened and 36 patients were qualified for analysis.
Thirty-six percentage of patients developed HBV reactivation and 17% developed HBV hepatitis together with
reactivation, one of which developed decompensate cirrhosis. Only 50% of patients accepted lamivudine although
all patients were recommended antiviral prophylaxis with entecavir or tenofovir and only 31% continued during
DMARDs therapy. Seventy-one percentage of patients who discontinued antiviral prophylaxis developed HBV
reactivation 3 ~ 21 months after discontinuation. Logistic regression analyses showed discontinuation of antiviral
prophylaxis (OR: 66, p = 0.027), leflunomide (OR: 64, p = 0.011) and past history of hepatitis (OR: 56, p = 0.013) were
risk factors of HBV reactivation. Past history of hepatitis (OR: 10, p = 0.021) was also risk factor of HBV hepatitis together
with reactivation.
Conclusion: Our results suggest poor patient acceptance and discontinuation of antiviral prophylaxis should not
be ignored for Chinese RA patients with HBV carrier state in real-world clinical practice. Discontinuation of
antiviral prophylaxis, past history of hepatitis and LEF might increase risk of HBV reactivation for RA patients with HBV
carrier state during DMARDs therapy.
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Chronic hepatitis B virus (HBV) infection is defined as
the presence of positive surface antigen of HBV (HBsAg)
more than 6 months and generally classified into HBV
hepatitis with fluctuant alanine amino-transferase (ALT)
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unless otherwise stated.Chronic HBV infection is a global healthcare problem
affecting more than 350 million people around the world
with potential poor prognosis of cirrhosis, hepatocarci-
noma or death [1,2]. Our previous study reported the
prevalence of chronic HBV infection among Chinese
rheumatoid arthritis (RA) patients was 11.2%, similar
with the prevalence of the age-matched general Chinese
population [1,3]. It is estimated 300,000 ~ 600,000 Chinese
RA patients with chronic HBV infection.
The prevalence of HBV reactivation was estimated
50% among patients with hematology-oncology diseasess is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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severe outcomes including hepatitis, acute liver failure,
cirrhosis or death in 5% ~ 30% of patients [4]. Inter-
national associations for the study of liver disease rec-
ommended antiviral prophylaxis should be used before
immunosuppressive therapy and continued minimal
6 ~ 12 months after suspension of immunosuppressant
for chronic HBV infection patients [5-7], based on clin-
ical evidences derived from hematology-oncology field.
However, there’re great differences of host immune sta-
tus, the types and intensity of immunosuppressant be-
tween RA patients and hematology-oncology patients.
Recommendations for disease-modifying antirheumatic
drugs (DMARDs) from American College of Rheumatology
(ACR) in 2008 suggested that minocycline, sulfasala-
zine (SSZ) under antiviral prophylaxis and hydroxy-
chloroquine (HCQ) could be used for RA patients with
HBV carrier state and liver function of Child-Pugh class A
(a scoring system for chronic liver disease), while metho-
trexate (MTX) and leflunomide (LEF) were contraindi-
cated [8]. ACR 2012 update recommended that biologic
DMARDs should also be used with antiviral prophylaxis
in these patients [9]. That is to say, long-term antiviral
prophylaxis should be used for RA patients with HBV
carrier state due to long-term DMARDs treatment. How-
ever, in real-world clinical practice, antiviral prophylaxis
may not be continued even not accepted due to high eco-
nomic burden, poor patient compliance or efficacy/safety
of antiviral drugs. To explore the risk of HBV reacti-
vation in RA patients with HBV carrier state during
DMARDs therapy and the use of antiviral prophylaxis in




Consecutive and hospitalized RA patients from July 2007
to September 2013 at department of Rheumatology,
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
were screened. All RA patients fulfilled 1987 ACR re-
vised criteria or 2010 ACR/European League Against
Rheumatism (EULAR) criteria. RA Patients with HBV car-
rier state who had positive HBsAg, normal ALT ≥ 6 months
and normal total billirubin (TBiL) were included. Pa-
tients with HBV hepatitis or other types of viral hepatitis,
autoimmune hepatitis, drug-induced hepatitis, cirrhosis
or hepatocarcinoma were excluded. All patients gave
written informed consent for this study, which was ap-
proved by the Ethics Committee of Sun Yat-Sen Memorial
Hospital.
Study design
Clinical data such as demographic characteristics, RA
disease activity evaluation, liver evaluation, HBV infectionevaluation and therapeutic regimens were recorded during
follow-up period without interference with physicians’
therapeutic strategies. Liver evaluation included serum
ALT, TBiL and if necessary, liver ultrasonography. HBV
infection evaluation included serum HBV-DNA and
HBV serological markers including HBsAg and its anti-
body (HBsAb), antigen e of HBV (HBeAg) and its anti-
body (HBeAb), antibody to HBV core antigen (HBcAb).
Serum HBV-DNA was detected by quantitative real-time
PCR by fluorogenic probe method with a lower limit
of detection of 103copies/mL. HBV serological markers
were qualitatively detected by ELISA.
Outcomes
The primary outcome was HBV reactivation, which was
defined as a 10-fold rise in HBV-DNA compared to
baseline or a switch from undetectable to detectable,
and/or HBeAg seroconversion from negative to positive
[4]. The secondary outcome was HBV hepatitis de-
fined as ALT > 80U/L after reactivation, with or without
icterus [10].
Statistical analysis
Statistical analysis was performed with SPSS for Windows
13.0 (SPSS Inc., Chicago, IL, USA). The non-parametric
Mann–Whitney U test or Fisher’s exact probabilities test
were used for between-group comparison. Survival curve
by Kaplan–Meier method and log-rank test was used to
estimate the occurrence time of HBV reactivation. Step-
forward logistic regression analysis was used to find out
the risk factors of HBV reactivation and the following HBV
hepatitis, counting odds ratio (OR) and its 95% of confi-
dence interval (CI). A p-value of less than 0.05 was consid-
ered to be significant.
Results
Baseline characteristics of the study patients
Four hundred and ninety-six consecutive and hospital-
ized RA patients were screened. Three patients with
HCV hepatitis, one patient overlapping with autoimmune
hepatitis and two patients with drug-induced hepatitis
were excluded. None of these six patients had positive
HBsAg. Seven patients with HBV hepatitis were not in-
cluded either.
Fifty-three RA patients with HBV carrier state were in-
cluded. Two patients overlapping with systemic lupus er-
ythematosus and one patient combined with lower limbs
vasculitis were excluded due to high-dose corticosteroids
or different immunosuppressants (e.g. cyclophosphamide).
Eight patients were unwilling to be followed up. Six pa-
tients lost follow-up due to home migration or change
to Chinese herbal therapy. Finally, 36 patients were quali-
fied for statistics (Figure 1).Their baseline characteristics
were shown in Table 1. Twenty-six patients (72%) were in
Figure 1 Flowchart shows the development of hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients with HBV
carrier state with and without antiviral prophylaxis and who discontinued antiviral prophylaxis.
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Before enrollment, 24 patients (67%) had never received
any DMARD or corticosteroid, while the other 12 patients
had received corticosteroid (n = 8), MTX (n = 9), LEF
(n = 8), SSZ (n = 4) or HCQ (n = 1).
Serum HBV-DNA was undetectable (<103copies/mL)
in 20 patients and the median of serum HBV-DNA in
the other 16 patients was 4.2 × 104 copies/mL (range,
1 × 103 ~ 1.5 × 108). Positive HBeAg was detected in 2
patients with undetectable HBV-DNA and 5 patients
with detectable HBV-DNA. There was no significant dif-
ference of baseline characteristics between patients with
undetectable and detectable HBV-DNA, except that ALT
was significantly higher in the latter than in the former
(P < 0.05, Table 1) and both ALT were not exceeding nor-
mal range.
HBV reactivation in RA patients with HBV carrier state
Antiviral prophylaxis was recommended for all RA pa-
tients with HBV carrier state, but only 18 patients (50%)
accepted. Entecavir and tenofovir were recommendedto these patients. However, only lamivudine was ac-
cepted for economic reason. Sixty-three percentage
(10/16) of patients with detectable baseline HBV-DNA
accepted antiviral prophylaxis, which tended to be higher
than 40% (8/20) of patients with undetectable base-
line HBV-DNA (Table 2), but no statistical signifi-
cance between these two groups was found. Three of
seven patients with positive HBeAg accepted antiviral
prophylaxis. The median follow-up period was 17.5 months
(range, 12 ~ 70 months). HBV-DNA and HBV sero-
logical markers of each included patient both at baseline
and at the end of follow-up were shown in Additional
file 1.
Thirty-six percentage (13/36) of RA patients with
HBV carrier state developed HBV reactivation during
DMARDs therapy and 17% (6/36) developed HBV hepa-
titis together with reactivation. Among patients with un-
detectable baseline HBV-DNA, 40% (8/20) had a switch
of serum HBV-DNA from undetectable to detectable.
Among patients with detectable baseline HBV-DNA,
31% (5/16) had a 10-fold rise in serum HBV-DNA
Table 1 Baseline characteristics and therapeutic regimens during follow-up of 36 RA patients with hepatitis B virus
(HBV) carrier state▲
All Patients (n = 36) Baseline serum HBV DNA
Undetectable (n = 20) Detectable (n = 16)
Demographic characters
Age (years) 46 ± 15 45 ± 15 48 ± 16
Female proportion 28 (78%) 14 (70%) 14 (88%)
Disease status
Disease duration (months), median (range) 21 (2 ~ 360) 11 (2 ~ 240) 24 (2 ~ 360)
Past history of hepatitis 9 (25%) 5 (25%) 4 (25%)
DAS28-crp, mean ± SD (range) 4.2 ± 1.6 (1.2 ~ 7.6) 4.4 ± 1.7 (1.2 ~ 7.4) 3.9 ± 1.6 (1.7 ~ 7.6)
RF positive rate 21 (58%) 11 (55%) 10 (63%)
Anti-CCP antibody positive rate 17 (47%) 12 (60%) 5 (31%)
CRP (mg/L) 25 ± 33 28 ± 35 20 ± 32
ESR (mm/1 h) 49 ± 43 55 ± 48 40 ± 35
ALT (U/L) 19 ± 10 17 ± 12 21 ± 6#
Total bilirubin (μmol/L) 8 ± 4 8 ± 2 11 ± 5
Therapeutic regimens during follow-up
MTX 3 (8%) 2 (10%) 1 (6%)
LEF* 2 (6%) 2 (10%) 0 (0%)
HCQ 1 (3%) 0 (0%) 1 (6%)
MTX + LEF 5 (14%) 3 (15%) 2 (13%)
MTX + SSZ 3 (8%) 2 (10%) 1 (6%)
MTX + HCQ 10 (28%) 4 (20%) 6 (38%)
MTX + HCQ + SSZ 12 (33%) 7 (35%) 5 (31%)
Low-dose Corticosteroid 29 (81%) 15 (75%) 14 (88%)
TNF-α antagonist△ 4 (11%) 4 (20%) 0
▲Data were described with mean ± standard deviation (SD) or number (precentage) unless stated otherwise. DAS28-crp = Disease Activity Score with 28-joint
counts modified by CRP; RF = rheumatoid factor; anti-CCP = anti-cyclic citrullinated peptide antibody; CRP = C-reactive protein; ESR = erythrocyte sedimentation
rate; ALT = alanine aminotransferase; MTX =methotrexate; LEF = leflunomide; SSZ = sulfasalazine; HCQ= hydroxychloroquine; NSAIDs = non-steroidal anti-inflammatory
drugs; TNF = tumor necrosis factor.
*Patients with MTX intolerance due to gastrointestinal discomfort.
△recombinant human TNF-аreceptor: IgG Fc fusion protein (50 mg/w) was given to 2 patients for 4 weeks and infliximab was given to the other 2 patients at a
dose of 200 mg for 3 times.
#Compared to patients with undetectable baseline HBV DNA, P < 0.05.
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prevalence of HBV reactivation between the above two
groups of patients (p > 0.05, Table 2). Clinical, serological
and virological characteristics of all 13 RA patients with
HBV reactivation were shown in Table 3. None of them
accompanied with HBeAg seroconversion from negative
to positive.Table 2 Antiviral prophylaxis, HBV reactivation and HBV hepa
detectable baseline HBV-DNA△
Baseline HBV DNA Antiviral prophylaxis
Yes* Discontinuation
Undetectable (n = 20) 4 (20%) 4 (20%)
Detectable (n = 16) 7 (44%) 3 (19%)
*Patients who discontinued antiviral prophylaxis were not included.
△all P > 0.05.Risk factors of HBV reactivation in RA patients with HBV
carrier state
Therapeutic regimens for RA during follow-up were
shown in Table 1. Low-dose MTX (≤15 mg/w) or
MTX + LEF therapy was prescribed for patients respond-
ing insufficiently to the original DMARD(s) therapy, in-
tolerant to other DMARDs, in moderate to high diseasetitis between RA patients with undetectable and
HBV reactivation HBV hepatitis
No
12 (60%) 8 (40%) 2 (10%)
6 (37%) 5 (31%) 4 (25%)
Table 3 Clinical, serological and virological characteristics in 13 rheumatoid arthritis (RA) patients with HBV reactivation during immunosuppressive therapy▲
Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Patient 11 Patient 12 Patient 13
Age/Gender 53/M 39/F 42/F 54/F 71/F 26/F 45/F 55/F 36/F 54/M 17/F 21/M 51/F
Past history of hepatitis no yes no no no yes no no no yes yes yes yes
HBeAg, baseline/reactivation −/− −/− −/− −/− −/− −/− +/+ −/− −/− −/− +/+ +/+ −/−
Viral loads at baseline
(Copies/mL)
<103 <103 <103 1.0 × 103 <103 <103 <103 <103 7.03 × 103 1.22 × 103 3.18 × 105 <103 1.0 × 103
Viral loads at reactivation
(Copies/mL)
3.64 × 105 7.87 × 103 1.92 × 103 2.47 × 104 6.98 × 103 1.15 × 104 3.01 × 103 4.01 × 103 9.91 × 105 1.41 × 107 1.78 × 108 5.26 × 107 1.59 × 107
ALT at baseline (U/L) 8 8 20 19 10 6 15 15 11 30 17 20 27
ALT at reactivation (U/L) 26 20 39 24 26 8 16 123 103 103 825 1880 1274
Therapeutic regimens during follow-up
Corticosteroid 7.5-10 mg/d no no 2.5-10 mg/d 5-10 mg/d 10 mg/d 10 mg/d 2.5-10 mg/d 10 mg/d 7.5-10 mg/d 7.5-10 mg/d no 5-7.5 mg/d
DMARDs MTX + LEF MTX + HCQ +
SSZ
MTX + LEF MTX + HCQ MTX + SSZ LEF MTX +HCQ+
SSZ
MTX + LEF MTX +HCQ+
SSZ
MTX + HCQ MTX + LEF LEF MTX + HCQ +
SSZ
Antiviral prophylaxis no Dis no Dis Dis no no no LAM LAM Dis Dis no
Time to reactivation (months) 22 24 26 15 10 18 3 22 8 14 5 6 25
Follow-up period (months) 33 43 34 25 22 35 6 52 10 18 11 7 25
HBV hepatitis no no no no no no no Anicteric Anicteric Anicteric Icteric Icteric Icteric,
cirrhosis
Treatment adjustment after HBV reactivation
Adjustments in DMARDs MTX + HCQ +
SSZ
no no no no no no HCQ MTX +HCQ+
SSZ
HCQ SSZ HCQ withdrawal
Antiviral drugs LAM no no no no no no LAM Adefovir
dipivoxil
telbivudine LAM entecavir telbivudine
▲The sequences of patients were numbered according to the date of HBV reactivation.
HBV = Hepatitis B virus; F = female; M =male; HBeAg = antigen e of HBV; ALT = alanine aminotransferase; DMARDs = disease-modifying antirheumatic drugs; MTX =methrotrexate; LEF = Leflunomide; HCQ= hydroxychloroquine;
SSZ = sulfasalazine.
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of 5 patients (80%) taking MTX+ LEF developed HBV re-
activation, which was significantly higher than 21% (6/28)
in patients taking MTX alone or other MTX-based
DMARD combinations, p = 0.021, Fisher’s Exact Test. Four
patients have received TNF-α antagonist for 4 ~ 6 weeks.
After receiving TNF-α receptor: IgG Fc fusion protein
(50 mg/w) for 4 weeks, one of two patients changed to
MTX+ LEF therapy for economic reason and developed
HBV reactivation 21 months later (Patient 1 in Table 3);
and the other changed to MTX+HCQ+ SSZ + Lamivu-
dine therapy and kept undetectable HBV-DNA and normal
ALT. After receiving infliximab for 3 times, one of two
patients changed to MTX+HCQ+ SSZ therapy and devel-
oped HBV reactivation 22 months later (Patient 2 in
Table 3); and the other changed to MTX+ LEF therapy
and developed HBV reactivation 24 months later (Patient 3
in Table 3).
Seven of 18 patients discontinued lamivudine 1 ~
7 months later by themselves due to high drug cost
and 71% of them (5/7) developed HBV reactivation 3 ~
21 months after discontinuation of lamivudine (Table 3).
The prevalence of HBV reactivation in patients who dis-
continued antiviral prophylaxis was 71% (5/7), which
tended to be higher than 33% (6/18) in patients without
antiviral prophylaxis or 18% (2/11) in patients with
continuous antiviral prophylaxis (Figure 1), although
no significant difference was found perhaps due to small
sample size (p = 0.122). Notably, survival curve showed the
median occurrence time of HBV reactivation in patients
who discontinued antiviral prophylaxis was 10 months
(95%CI: 1.7 ~ 18 months), which was earlier than that in
patients without antiviral prophylaxis, 25 months (95%CI:
20 ~ 30 months) (χ2 = 10.754, p = 0.005, Figure 2). TwoFigure 2 Survival curve of hepatitis B virus (HBV) reactivation in patie
who discontinued antiviral prophylaxis (red) during immunosuppresspatients with baseline HBV-DNA of 7.03 × 103copies/mL
or 1.22 × 103copies/mL developed HBV reactivation 8 or
14 months later although continuous antiviral prophylaxis
with lamivudine (Patient 9 and 10 in Table 3).
Logistic regression analysis was performed on vari-
ables including age, past history of hepatitis, baseline
HBeAg, baseline load of HBV-DNA, immunosuppressants
(such as corticosteroid, MTX, LEF, SSZ, HCQ) and anti-
viral prophylaxis. Discontinuation of antiviral prophylaxis
(OR: 66, p = 0.027), LEF (OR: 64, p = 0.011) and past his-
tory of hepatitis (OR: 56, p = 0.013) were risk factors of
HBV reactivation for RA patients with HBV carrier state
during DMARDs therapy (Table 4). Further analysis
showed patients with past history of hepatitis had a higher
prevalence of HBV reactivation than those without, 78%
(7/9) vs. 22% (6/27), p = 0.005, Fisher’s Exact Test.
HBV hepatitis after HBV reactivation in RA patients with
HBV carrier state
Among 13 RA patients with HBV reactivation, 6 patients
(46%) developed HBV hepatitis together with reactiva-
tion. Three patients (23%) developed icteric hepatitis
and all of these three patients had past history of icteric
hepatitis. Logistic regression analysis on the above vari-
ables showed past history of hepatitis was also risk fac-
tor of HBV hepatitis after HBV reactivation (OR: 10,
p = 0.021, Table 4). Further analysis showed patients with
past history of hepatitis had a higher prevalence of HBV
hepatitis following reactivation than those without, 44%
(4/9) vs 7% (2/27), p = 0.024, Fisher’s Exact Test.
The prevalence of HBV hepatitis in patients with HBV-
DNA ≥ 105 copies/mL at reactivation was 83% (5/6), which
was significantly higher than 14% (1/7) in patients with
HBV-DNA< 105 copies/mL at reactivation (p = 0.029).nts with (green) or without antiviral prophylaxis (blue) or those
ive therapy.
Table 4 Step-forward logistic regression analysis on the risk factors of HBV reactivation and HBV hepatitis
Coefficient Standard error Wald χ2 P Odds ratio 95% CI
Lower Upper
Risk factors of HBV reactivation
Leflunomide 4.2 1.6 6.5 0.011 64 2.6 1591
Discontinuation of antiviral prophylaxis 4.2 1.9 4.9 0.027 66 1.6 2675
Past history of hepatitis 4.0 1.6 6.1 0.013 56 2.3 1355
Constant −4.2 1.6 6.5 0.011 0.016
Risk factor of HBV hepatitis
Past history of hepatitis 2.3 1.0 5.4 0.021 10 1.4 70
Constant −2.5 0.7 11.8 0.001 0.08
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Six of 7 patients with HBV-DNA < 105 copies/mL at
reactivation (patient 2 ~ 7 in Table 3) were followed up
closely without antiviral therapy or DMARDs adjust-
ment and their HBV-DNA returned to undetectable
8 ~ 19 months later. The other one patient with HBV
hepatitis although HBV-DNA < 105 copies/mL at reacti-
vation (patient 8 in Table 3) was treated with lamivudine
together with HCQ instead of MTX + LEF. Her serum
ALT returned to normal and serum HBV-DNA returned
to undetectable two months later. However, with relapsed
disease activity (DAS28 = 3.6), she was then treated with
MTX +HCQ and reached low disease activity 2 months
later.
Treatment adjustment of DMARDs for 6 patients with
HBV-DNA ≥ 105 copies/mL at reactivation was shown in
Table 3. Patient 1 and patient 13 who have not accepted
antiviral prophylaxis were prescribed antiviral therapy,
and patient 1 chose lamivudine for economic reason. Pa-
tient 11 and 12 who have discontinued antiviral prophy-
laxis was prescribed antiviral therapy, and patient 11
chose lamivudine for economic reason. Patient 9 and 10
who have chosen lamivudine as antiviral prophylaxis
were changed to adefovir dipivoxil and telbivudine,
respectively. HBV-DNA of patient 1 returned to undetect-
able 11 months later. Serum ALT of patient 9 ~ 12
returned to normal and serum HBV-DNA decreased 2 ~
3 months later (still in follow-up). Patient 13 stopped all
DMARDs after developing icteric hepatitis and decompen-
sate cirrhosis.
Discussion
This study provided follow-up records of 36 RA patients
with HBV carrier state ranging 12 ~ 70 months in real-
world clinical practice and the prevalence of HBV reacti-
vation for RA patients with HBV carrier state during
DMARDs therapy was found as high as 36% and the
prevalence of HBV hepatitis together with reactivation
was 17%. Our study first highlighted poor patient ac-
ceptance and discontinuation of antiviral prophylaxis forChinese RA patients with HBV carrier state. Using sur-
vival curve and multivariate regression analysis, our
results demonstrated two innovative risk factors of HBV
reactivation for RA patients with HBV carrier state
during DMARDs therapy, discontinuation of antiviral
prophylaxis and past history of hepatitis.
DMARDs can cause unopposed HBV replication or re-
activation in liver by suppressing host immune response
(e.g. HBV-specific cytotoxic T lymphocyte) [11]. Therefore,
HBV reactivation is described mainly on virological terms
about serum HBV-DNA with a 10-fold rise or switching
from undetectable to detectable. HBeAg seroconversion
from negative to positive is also a definition of HBV reacti-
vation. However, our result showed that none of 10 pa-
tients with HBV reactivation and negative HBeAg had
HBeAg seroconversion. Abolishing or downregulating the
production of HBeAg may be partly explained by muta-
tions of the precore or basal core prompter [12]. Detection
of serum HBV-DNA may be more important than HBeAg
while monitoring the occurrence of HBV reactivation.
Clinical manifestations of HBV reactivation were attrib-
uted to elevated HBV-DNA replication and liver injury.
Elevated HBV-DNA replication, although asymptomatic
sometimes, can induce random integration of HBV-DNA
into the host DNA in hepatocytes [6], leading to increased
risk of hepatocarcinoma and decreased likelihood of HBV
eradication. Liver injury manifests as elevated ALT with or
without jaundice. Repeated high ALT peaks with failure to
suppress HBV replication were shown to predict higher
rates of cirrhosis [13]. Our results showed nearly half of
RA patients with HBV reactivation developed HBV hepa-
titis and one patient developed decompensate cirrhosis,
indicating poor outcomes of HBV reactivation for RA pa-
tients with HBV carrier state during DMARDs therapy.
Poor patient acceptance and discontinuation of antiviral
prophylaxis should not be ignored for Chinese RA
patients with HBV carrier state
Antiviral prophylaxis was recommended by ACR for RA
patients with chronic HBV infection during DMARD
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cleotide analogs with high antiviral potency and a high
barrier to resistance, are both recommended as first line
antiviral drugs for patients who have a high HBV-DNA
level and/or may receive a lengthy and repeated cycles of
immunosuppression (e.g. long-term DMARDs therapy) by
European [7], American [6] and Asian-Pacific [5] associa-
tions for the study of liver disease. However, in this real-
world study, although all patients were recommended
entecavir or tenofovir, only 50% of patients accepted lami-
vudine as antiviral prophylaxis. The most important rea-
son was the cost of antiviral drug, which is much more
expensive than conventional DMARDs causing high eco-
nomic burden for self-paid RA patients, not only in
developing countries but also in developed countries
[14]. Lamivudine resistance (up to 70% in 5 years) usually
occurs after 6–9 months of lamivudine therapy and is
responsible for virus breakthrough [5]. Lamivudine resist-
ance partly correlates with YMDD mutation, which
develops in 15% ~ 30% per year of HBV patients on
lamivudine prophylaxis [15]. Our results showed two pa-
tients with continuous lamivudine prophylaxis developed
HBV reactivation and hepatitis 8 or 14 months later, with
regret that YMDD motif mutation of HBV was not
tested. Ryu et al. [16] reported one case of HBV reactiva-
tion occurred due to YMDD mutation after long-term
use of lamivudine in a retrospective study included 15
patients received biological DMARDs under lamivudine
prophylaxis.
Withdrawal of antiviral drug usually resulted in re-
bound of HBV-DNA, accompanying with “flare” of ALT
in 19 ~ 50% of patients [17]. Our study showed 71% of
patients who discontinued antiviral prophylaxis devel-
oped HBV reactivation 3 ~ 21 months after discontinu-
ation. Both survival curve and regression analysis proved
that discontinuation of antiviral prophylaxis was risk fac-
tor of HBV reactivation for RA patients with HBV carrier
state during DMARDs therapy. Therefore, discontinuation
of antiviral prophylaxis may be important reason for high
prevalence of HBV reactivation in our observational study.
Thus, antiviral prophylaxis should be insisted once begun
and continued minimal 6 ~ 12 months after suspension of
immunosuppressant. Rheumatologists should choose anti-
viral drugs according to guidelines and informing patients
the serious consequences of antiviral drugs discontinuation
at each interview.
Low-dose MTX may be alternative for RA patients with
HBV carrier state to control RA disease activity, while LEF
should be contraindicated
Not only the risk of HBV reactivation but also the effect
of DMARDs on disease activity should be considered
when choosing DMARDs for RA patients with HBV car-
rier state. HCQ, minocycline, SSZ or SSZ + HCQ whichcan be used for RA patients with HBV carrier state ac-
cording to guidelines [8,9] was sometimes inadequate to
control moderate to high disease activity, while biologic
DMARDs are usually expensive for self-paid patients.
Although contraindicated by guidelines [8] MTX and/or
LEF sometimes have to be used for controlling RA dis-
ease activity. One patient in our study had repeated re-
lapse of RA disease activity when taking HCQ alone
after HBV reactivation and HBV hepatitis. After low-
dose MTX was added with HCQ, her disease activity
was controlled to low disease activity.
In this real-world study, 72% of RA patients had mod-
erate to high disease activity and MTX-based DMARD
combination therapy had to be used. Our study showed
the prevalence of HBV reactivation in patients taking
MTX + LEF was 80%, which was significantly higher
than 21% in patients taking MTX alone or other MTX-
based DMARD combination therapy. Further regression
analysis showed LEF, but not MTX, was risk factor of
DMARD-induced HBV reactivation. It was reported that
LEF probably activated HBV replication by a nucleotide-
reduction–associated increase of mitogen-activated pro-
tein kinase (MAPK) p38 phosphorylation in vitro [18].
LEF is also a hepatotoxic drug causing transient eleva-
tion of serum ALT in more than 5% of patients [19].
Therefore, LEF should be contraindicated for RA pa-
tients with HBV carrier state, while low-dose MTX may
be alternative to control moderate to high RA disease
activity. One literature review supported this assumption
and showed most cases were treated with MTX as a
preferred choice [20]. However, 21% of patients taking
MTX+ non-LEF DMARDs combination therapy developed
HBV reactivation in our study and there are sporadic case
reports on MTX-induced HBV reactivation [21-23]. Fur-
ther prospective cohort study is required to explore the
safety and effective of low-dose MTX+ non-LEF DMARDs
combination therapy with antiviral therapy for RA patients
with HBV carrier state.
Additionally, corticosteroid might promote HBV repli-
cation by activating glucocorticoid responsive elements
(GRE) on HBV and the risk of high-dose corticosteroid
on HBV reactivation in oncology-chemotherapy pa-
tients has been comfirmed [11]. Other than patients with
hematology-oncology diseases or some other rheumatic
diseases, low-dose glucocorticoids should be considered as
part of the initial treatment strategy (in combination with
one or more conventional DMARDs) for RA patients for
up to 6 months, but should be tapered as rapidly as clinic-
ally feasible according to 2013 EULAR recommendations
[24]. One small-scale prospective study showed coadmin-
istration of low-dose corticosteroid had a significant cor-
relation with HBV reactivation among RA patients with
HBV carrier state without antiviral prophylaxis [25]. Our
study did not find corticosteroid as a risk factor of HBV
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http://www.biomedcentral.com/1471-2474/15/449reactivation for RA patients with HBV carrier state during
DMARDs therapy. Since our study included more patients
(81%) taking low-dose corticosteroid, further study with
larger sample size is needed to evaluate the exact risk of
low-dose corticosteroid on HBV reactivation for RA pa-
tients with HBV carrier state during DMARDs therapy.
One of limitations in this study was lack of data about
biologic DMARDs, since only 4 patients receiving TNF-
α antagonist for 4 ~ 6 weeks were included. HBV reacti-
vation occurred 21 ~ 24 months after discontinuation of
TNF-α antagonist in 3 patients, which might be attrib-
uted to subsequent conventional DMARDs, rather than
TNF-α antagonist. Recently, Costa et al. [26] reported
long-term use of TNF-α antagonist alone was safe for 15
psoriatic arthritis patients with chronic hepatitis C virus
(HCV) infection in the absence of specific therapy for
HCV. Giannitti et al. [27] reported tocilizumab combined
with cyclosporine-A was effective and safe for a RA patient
with chronic HCV infection. Cyclosporine-A could control
HCV replication by inhibition of cyclophilin-B (while the
inhibition of calcineurin causes immunosuppressive effect)
and may be safe in patients with autoimmune disorders
and concomitant HCV infection [28]. However, litter is
known about the safety of cyclosporine-A in patients with
RA and concomitant HBV infection. Additionally, RA pa-
tients who were HBsAg-negative anti-HBc-positive poten-
tial occult carriers [29] should also be emphasized.Conclusions
The results of our study suggest that poor patient ac-
ceptance and discontinuation of antiviral prophylaxis
should not be ignored for Chinese RA patients with
HBV carrier state in real-world clinical practice. Discon-
tinuation of antiviral prophylaxis, past history of hepa-
titis and LEF might increase risk of HBV reactivation for
RA patients with HBV carrier state during DMARDs
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